HUTCHMED’s Post

Their abstract: Despite significant advances over recent years, the treatment of T cell acute lymphoblastic leukemia (T-ALL) remains challenging. We have recently shown that a subset of T-ALL cases exhibited constitutive activation of the lymphocyte-specific protein tyrosine kinase (LCK) and were consequently responsive to treatments with LCK inhibitors and degraders such as dasatinib and dasatinib-based PROTACs. Here we report the design, synthesis and in vitro/vivo evaluation of SJ45566, a potent and orally bioavailable LCK PROTAC.

Despite significant advances over recent years, the treatment of T cell acute lymphoblastic leukemia (T-ALL) remains challenging. We have recently shown that a subset of T-ALL cases exhibited constitutive activation of the lymphocyte-specific protein tyrosine kinase (LCK) and were consequently responsive to treatments with LCK inhibitors and degraders such as dasatinib and dasatinib-based #PROTACs. Here we report the design, synthesis and in vitro/vivo evaluation of #SJ45566, a potent and orally bioavailable LCK #PROTAC. #Protac #PDC #SmallMolecule #Medchem #Medcinal #FFS #FTE #CDMO #CMC

New therapeutic approaches are needed to cure the patients who currently still relapse and die from acute lymphoblastic leukemia (ALL) and to mitigate current treatment intensity and side-effects. Read here the new review on available antibodies for the treatment of childhood ALL: bispecific antibodies, antibody-drug conjugates and monoclonal antibodies. https://lnkd.in/dChQrvYi

Asciminib, a BCR::ABL1 inhibitor targeting the ABL myristoyl pocket, demonstrated superior efficacy and safety compared to tyrosine kinase inhibitors in the phase 3 ASC4FIRST trial for newly diagnosed chronic-phase chronic myeloid leukemia (CML) patients. Read Viewpoint in Med by Cell Press. #ChronicMyeloidLeukemia #CML #TyrosineKinaseInhibitors #Asciminib #ASC4FIRST https://lnkd.in/ei6cKc48

Could your patients be eligible for the KOMET-008 clinical trial aimed at evaluating ziftomenib, a menin inhibitor, with other existing standard-of-care treatments in relapsed or refractory acute myeloid leukemia? Hematologist-oncologist Harry Erba, MD, PhD, explains the different combinations KOMET-008 will evaluate and how it differs from KOMET-007. KOMET-008 is OPENING SOON. Learn more: https://lnkd.in/g37mAZZq

Asuragen's QuantideX® qPCR PML-RARA Kit offers sensitive and scalable detection of three PML-RARA aberrant fusions in a single, multiplex RT-qPCR reaction, with results in less than five hours. Bcr1, bcr2, and bcr3 aberrant fusions of the PML-RARA, these fusions are crucial indicators of acute promyelocytic leukemia (APL), a distinct and aggressive subtype of acute myeloid leukemia (AML). Learn more: https://bit.ly/45917Ub #Asuragen #qPCR #mygulfscientific #gulfscientificcorporation

More than 30 years ago, Bispecific T-cell Engager (BiTE®) technology was developed with the goal of finding new ways to help people facing the toughest-to-treat cancers. These efforts came to fruition nearly a decade ago, when Amgen's novel immunotherapy became the first globally approved BiTE® molecule, expanding options for people with advanced B-cell lineage acute lymphoblastic leukemia (B-ALL), a patient population with historically dismal outcomes and limited treatment options. Over the past ten years, it’s been inspiring to see our T-cell engager impact relapsed or refractory and measurable residual disease (MRD)-positive B-ALL patients. Now with @FDA approval for Ph-negative B-ALL patients regardless of their MRD status, Amgen is again poised to transform possibilities for people with this aggressive blood cancer. Read more👇#MyCompany

Chronic myeloid leukemia (CML) is a slowly progressing cancer that affects the blood and bone marrow. IkT-001Pro has received Orphan Drug Designation for stable-phase CML and will follow the development pathway for approval through the 505(b)(2) regulation. https://bit.ly/3fMhg8O

Today is World CML Day. It was chosen to recognize chronic myeloid leukemia (CML) patients because 9/22 represents the genetic change of chromosomes 9 and 22, which is the cause of chronic myeloid leukemia. This annual observance, which has been recognized for more than 20 years, calls on the medical community to join in on global efforts to improve access to testing, treatments and more. #WorldCMLDay is special to our organization. NeoGenomics' mission is to save lives through improved patient care. We endeavor to remove the complexities of diagnosing cancer and to empower the medical community with the needed tools to provide patients with the best care possible. NeoGenomics enables precision oncology with the most advanced and comprehensive testing menu. You can search for CML in our test menu to view more than two dozen relevant tests: https://lnkd.in/ehFCJFnj

Inhibikase is developing IkT-001Pro to provide people suffering from chronic myelogenous leukemia (CML) with a new and improved, safer alternative to imatinib. Learn about our development of IkT-001Pro for CML here: https://bit.ly/3fMhg8O